Idera Pharmaceuticals (NASDAQ:IDRA) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.06, MarketWatch Earnings reports. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%.
Idera Pharmaceuticals stock traded up $0.52 during midday trading on Friday, reaching $3.58. The stock had a trading volume of 47,411 shares, compared to its average volume of 333,093. Idera Pharmaceuticals has a 12 month low of $2.25 and a 12 month high of $17.12. The firm has a market capitalization of $89.67 million, a price-to-earnings ratio of -1.59 and a beta of 2.59.
A hedge fund recently bought a new stake in Idera Pharmaceuticals stock. Dimensional Fund Advisors LP purchased a new stake in shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 22,099 shares of the biotechnology company’s stock, valued at approximately $61,000. Dimensional Fund Advisors LP owned about 0.08% of Idera Pharmaceuticals as of its most recent filing with the SEC. 44.56% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Idera Pharmaceuticals (IDRA) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS” was published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://weekherald.com/2019/05/03/idera-pharmaceuticals-idra-posts-quarterly-earnings-results-beats-estimates-by-0-06-eps.html.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.
Read More: How liquidity affects the bid-ask spread
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.